Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
28 May 2014 | By Sanofi
Sanofi and Eli Lilly and Company announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil)...
List view / Grid view
News
Bristol-Myers Squibb and Incyte enter clinical collaboration agreement to evaluate combination regimen of two novel immunotherapies
28 May 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Incyte Corporation announced the establishment of a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen...
Pfizer brings frequent heartburn relief over-the-counter with new Nexium® 24HR
28 May 2014 | By Pfizer
The nation’s most prescribed acid blocker brand is now available without a prescription at retailers nationwide...
Teva announces favorable European Patent Office ruling in COPAXONE® patent proceeding
28 May 2014 | By Teva
Teva Pharmaceutical Industries Ltd. announced that the European Patent Office issued a decision in favor of Teva in a patent opposition proceeding filed by Synthon BV, Mylan and an unidentified third party...
Amgen and Onyx Data at ASCO 2014 highlight oncology pipeline and portfolio
28 May 2014 | By Amgen
New data reinforces commitment to personalized medicine and highlights advances in immunotherapy platform...
Dainippon Sumitomo Pharma and Daiichi Sankyo cooperate on lurasidone, an atypical antipsychotic agent, in four South American countries
27 May 2014 | By Daiichi Sankyo
Dainippon Sumitomo Pharma Co., Ltd. and Daiichi Sankyo Co., Ltd. announced that they have entered into a license agreement for the commercialization of lurasidone hydrochloride...
Daiichi Sankyo launches the antiplatelet agent Efient® 3.75mg/5mg tablets
27 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has launched the antiplatelet agent Efient® 3.75mg/5mg Tablets in Japan...
Daiichi Sankyo receives approval in Japan for additional indication related to RANMARKⓇ for treatment of giant cell tumor of bone
23 May 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has received approval in Japan for partial modification to RANMARKⓇ...
CHMP recommends EU approval of Roche’s Gazyvaro™ for people with chronic lymphocytic leukemia
23 May 2014 | By Roche
Roche announced that the EU Committee for Medicinal Products for Human Use recommended that the European Commission approve Gazyvaro in combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukemia...
Novartis provides update on EU marketing authorization application for RLX030 in acute heart failure
23 May 2014 | By Novartis
Novartis announced that the Committee for Medicinal Products for Human Use has adopted a negative opinion for the use of RLX030 in the treatment of acute heart failure...
GSK announces regulatory submission for umeclidinium monotherapy for COPD in Japan
23 May 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for umeclidinium...
Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin)
23 May 2014 | By Boehringer Ingelheim
The European Commission has granted Marketing Authorisation for empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor from Boehringer Ingelheim and Eli Lilly and Company...
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
22 May 2014 | By Novartis
Novartis will showcase the results of research efforts to target disease pathways with more than 150 abstracts at two upcoming cancer-focused meetings...
Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
22 May 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces the next step in the clinical development of idarucizumab, the investigational antidote for rapid reversal of dabigatran-induced anticoagulation...
Sanford-Burnham and Daiichi Sankyo form alliance to study novel drug targets in cardiovascular-metabolic diseases
22 May 2014 | By Daiichi Sankyo
Sanford-Burnham Medical Research Institute and Daiichi Sankyo Co., Ltd. announced they have entered into a three-year comprehensive alliance to develop first-in-class therapeutics for the treatment of cardiovascular-metabolic diseases...
